Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Uveitis - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the decision...
-
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...
-
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Global Uveitis Treatment Market" report has been added to ResearchAndMarkets.com's offering.The global uveitis treatment market accounted for USD 753...
-
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Uveitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
-
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Uveitis Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The latest report on the...
-
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Autoimmune Uveitis Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ResearchAndMarkets.com's offering. ...
-
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution...
-
Dublin, July 31, 2023 (GLOBE NEWSWIRE) -- The "Uveitis - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This comprehensive...
-
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
-
Dublin, March 10, 2022 (GLOBE NEWSWIRE) -- The "Anterior Uveitis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's...